Last reviewed · How we verify
ADH -1 and docetaxel
ADH-1 is an angiostatic peptide that inhibits angiogenesis by binding to heparin sulfate proteoglycans on the surface of endothelial cells, while docetaxel is a microtubule inhibitor that blocks cell division.
ADH-1 is an angiostatic peptide that inhibits angiogenesis by binding to heparin sulfate proteoglycans on the surface of endothelial cells, while docetaxel is a microtubule inhibitor that blocks cell division. Used for Non-small cell lung cancer.
At a glance
| Generic name | ADH -1 and docetaxel |
|---|---|
| Sponsor | Adherex Technologies, Inc. |
| Drug class | angiostatic peptide and microtubule inhibitor |
| Target | heparin sulfate proteoglycans and tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ADH-1 works by binding to heparin sulfate proteoglycans on the surface of endothelial cells, preventing the formation of new blood vessels. Docetaxel, on the other hand, binds to tubulin and prevents the polymerization of microtubules, thereby blocking cell division.
Approved indications
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADH -1 and docetaxel CI brief — competitive landscape report
- ADH -1 and docetaxel updates RSS · CI watch RSS
- Adherex Technologies, Inc. portfolio CI